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INTRODUCTION
THE recognition of thyroid dysfunction in pregnancy is important for the
welfare of both mother and fetus. Obstetricians tend to think of the thyroid
disease as complicating the pregnancy, whereas physicians look at it the other
way round. Both viewpoints must be taken into consideration for neither
condition can be treated successfully if the other is neglected. The knowledge of
how the thyroid disease is affected by the pregnancy, and how the disease and
its treatment influences pregnancy and fetal development, is essential in deter-
mining the management of these patients.
The purpose of this paper is to review the changes that occur in thyroid
physiology in pregnancy and to report the extent of thyroid disease seen in
pregnancy in the Royal Maternity Hospital, Belfast, over a 16-year period,
1963 to 1978.
MATERNAL AND FETAL THYROID FUNCTION IN PREGNANCY
Maternal Factors
The physiological changes which occur in thyroid metabo!ism in pregnancy
have been reviewed by Selenkow et al (1973) and Tunbridge and Hall (1975).
Information on the interrelationship of maternal and fetal thyroid activity is
still incomplete, but some facts are fairly well known.
The BMR rises in pregnancy but this is mainly due to extrathyroidal factors.
The protein-bound iodine level is elevated as a result of increased thyroxine
binding capacity of the plasma protein, brought about by the secretion of
oestrogens during pregnancy. There is an increase in the renal clearance of
iodide which is associated with a lowering of the plasma inorganic iodine level.
The thyroid clearance of iodine and its uptake of radio-iodine are thus raised
to make up for the renal loss of iodide and the gland enlarges in response. This
has an important clinical application for it means that thyroid enlargement in
pregnancy per se is not necessarily due to a pathological process.
The placenta has been shown to secrete a thyroid stimulating factor called
human chorionic thyrotrophin. This may explain why the thyroid stimulating
activity of the plasma is greater in pregnant than in non-pregnant women and
it provides a further reason for the enlargement of the thyroid in pregnancy.
Recent evidence suggests human chorionic gonadotrophin may be the chorionic
thyrotrophin referred to. The activity of one IU of human chorionic gonado-
trophin is -equivalent to 0.5[tU of human TSH (Kenimer et al, 1975). However,
the role, if any, of this placental thyroid stimulator in the regulation of thyroid
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increased in pregnancy and is likely to be due to the enhanced sensitivity of the
pituitary thyrotroph cell brought about by the increased secretion of oestrogens.
Although the level of PBI, total T4 and total T3 rise in pregnancy it must
be remembered that it is not the bound but the free hormones which take part
in physiological processes. In pregnancy, the free T4 and T3 levels remain stable
and similar to those in non-pregnant controls and the rate of hormone production
and degradation is unaltered. Similarly, serum TSH values remain normal during
pregnancy. For these reasons one must conclude that the normal woman is
euthyroid throughout her pregnancy.
Fetal Factors
Not much is known about fetal thyroid metabolism. The earliest date that
iodinated proteins have been recovered from the thyroid is at the tenth week of
gestation and thyroxine is detectable in the serum by the eleventh week. This
means that, for the first 10 to 12 weeks or so of intrauterine life, the fetus has
no competent functioning thyroid tissue and must, presumably, depend on
maternal sources for thyroid hormone, if such is necessary for early development.
During the second trimester the fetal thyroid starts to synthesize hormone but
the activity of the gland is relatively low. The normal pituitary-thyroid axis
is established by the fourth or fifth month of gestation.
In the second trimester fetal PBI and total T4 concentrations are in the adult
hypothyroid range. However, since fetal thyroid binding protein is also low,
free T4 values are similar to those in the maternal circulation. By the end of
pregnancy, the fetal PBI, total T4 and thyroid binding protein are almost equal
to maternal levels. In contrast, fetal T3 levels are low before 24 weeks and
while they rise subsequently they remain much lower than maternal levels even
at term (Fisher et al, 1973). The concentration of thyroxine in amniotic fluid
remains relatively constant throughout pregnancy but triiodothyronine levels are
undetectable. Unexpectedly high values of reversed T3 (3, 3', 5'-triiodothyronine,
rT3), a hormone with little biological effect, are found between 15 to 30 weeks
but decrease substantially thereafter. Mean thyroxine and T3 values in amniotic
fluid are lower and rT3 levels are higher than the corresponding values in
maternal serum (Chopra and Crandall, 1975). The significance of the high
concentration of rT3 in amniotic fluid is not known.
At birth, cord T3 levels are low while rT3 levels are raised. In the hours
after birth serum T3 concentrations rise 200 to 400 per cent while T4 values
rise 25 to 50 per cent. The increase in T4 and part of the T3 rise is due to the
transient neonatal increase in TSH secretion. However, most of the rise in T3
must be due to a rapid postnatal increase in extrathyroidal conversion of T4
to T3.
The rate and extent of thyroid hormone transfer across the placenta remains
unsettled. There is evidence that free thyroxine will pass from mother to fetus
and that T3 is slightly more permeable, but the degree of transfer is low
(Selenkow et al, 1973). The reverse situation in which fetal thyroid hormone
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which we observed, the maternal T4 and T3 values rose, while TSH levels fell
to near normal as the pregnancy proceeded, presumably as the result of trans-
placental passage of hormone from fetus to mother. After delivery, the mother
rapidly became hypothyroid again (Kennedy and Montgomery, 1978). The
thyroid stimulating immunoglobulins, the immunoglobulins associated with
Graves' disease cross the placenta quite easily.
THYROID DISEASE IN PREGNANCY
Table I records the occurrence of thyroid disease observed in the Royal
Maternity Hospital from January 1963 to November 1978.
TABLE I
Thyroid disease in pregnancy. Royal Maternity Hospital,
Belfast 1963-78.
HYPERTHYROIDISM 73
Treated medically 68*
Treated surgically 3
No treatment 2*
HYPOTHYROIDISM 64t
NON-TOXIC GOITRE 59
Diffuse gland 39
Nodular gland 20
MISCELLANEOUS THYROID DISEASE 112
Total pregnancies 308
* Includes two cases of T., thyrotoxicosis.
t Includes two cases of untreated hypothyroidism.
Sixty-eight had their thyrotoxicosis treated with antithyroid drugs while thyro-
idectomy was performed in three. Two patients were untreated because they were
seen late in pregnancy. Sixty-four pregnancies occurred in hypothyroid mothers.
All but two were maintained in an euthyroid state with thyroxine during the
time they were under observation. In fifty-nine pregnancies a non-toxic goitre
was present. One hundred and twelve of the remaining pregnancies were
associated with miscellaneous forms of thyroid disease (Table II). Forty and
thirty-four had had previous medical or surgical treatment for thyrotoxicosis
and were euthyroid during their pregnancies. Seventeen had a thyroid cyst,
nodule or simple goitre removed earlier. A previous thyroiditis occurred in
eight, and ten women with carcinoma of the thyroid treated by total or subtotal
thyroidectomy had thirteen pregnancies between them. In one, the papilliary
carcinoma was first recognized in pregnancy and it was removed surgically at
the nineteenth week of gestation.
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or imperfect gland which may not be able to support the metabolic demands
of pregnancy. Hence, it is important to decide if the mother is euthyroid and
to monitor thyroid function throughout pregnancy.
TABLE II
Miscellaneous forms of thyroid disease. Royal Maternity Hospital,
Belfast 1963-78.
Previous medical treatment for Graves' disease 40
Previous thyroidectomy for Graves' disease 34
Previous removal of thyroid cyst or nodule or simple goitre 17
Thyroiditis 8
Carcinoma of thyroid 13
Total number of pregnancies 112
PREGNANCY AND HYPERTHYROIDISM
Hyperthyroidism complicates pregnancy in approximately 0.2 per cent of
cases (0.18 per cent in this series). Most commonly it results from Graves'
disease, but toxic nodular goitre is sometimes the cause. Usually the thyrotoxic-
osis antedates conception and the latter follows when the hyperthyroid state
has been brought under control by treatment. Fertility is impaired and rates
of abortion are higher in the untreated thyrotoxic than in normal women.
The diagnosis of hyperthyroidism in pregnancy is often difficult, especially
in milder cases, because physiological changes may mimic closely the features
of hyperthyroidism. Biochemical investigations may also be confusing because
of the changes in thyroid tests brought about by increases in thyroid binding
proteins. Pregnancy appears to ameliorate, to some extent, the severity of the
thyrotoxicosis so that clinical features may be mild. Radioactive iodine tests
administered to the mother must be avoided and reliance placed on the measure-
ment of T4, T3 and TSH. Circulating levels of total T4 and T3 rise in pregnancy
and, as the measurement of free (unbound) T4 and T3 is technically difficult
and usually not available, most reliance is placed on the free thyroxine index
(FfI) using the Thyopac-3 and Thyopac-4 kits (Radiochemical Centre, Amer-
sham). The normal pregnancy value of 90 + 17 is not far different from the
non-pregnant control level of 84 ± 21 and all euthyroid pregnant women fall
in the normal range (Bell et al, 1974). A similar free triiodothyronine index
can be obtained by using the Thyopac-3 result. The T3 red cell or resin uptake
test performed in vitro is also useful. In normal pregnancy the uptake is in the
hypothyroid range. In the thyrotoxic patient levels are usually in the low normal
range. The occurrence of T3 thyrotoxicosis in pregnancy will be missed if T3
values are not measured routinely, because the usual tests are unaltered in this
form of hyperthyroidism.
In spite of the help offered by laboratory investigations the diagnosis of
hyperthyroidism in pregnancy remains largely clinical. Reliance must be placed
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a good appetite, a high sleeping pulse rate, a significant goitre with increased
blood flow and the eye signs found in Graves' disease, such as periorbital
swelling, lid retraction and exophthalmos.
Treatment of thyrotoxicosis during pregnancy demands special care because
both disease and treatment carry special risks. The choice lies between antithyroid
drugs with or without thyroid hormone supplements and subtotal thyroidectomy
(Werner, 1967). Both have their proponents (Becker and Sudduth, 1959; Hawe
and Francis, 1962; Herbst and Selenkow, 1965; Talbert et al, 1970; Selenkow
et al, 1973; Goluboff et al, 1974). The choice between antithyroid drug treatment
and surgery is made on several grounds and need not be influenced unduly by
the pregnancy.
Subtotal thyroidectomy is indicated for patients with large goitres causing
obstruction, or those whose thyrotoxicosis cannot be controlled by reasonably
modest doses of antithyroid drugs (under 300 mg of propylthiouracil or 30 mg
of carbimazole daily) or who manifest toxic reactions to antithyroid drugs, or
for those who are unwilling to or unable to follow the medical regimen correctly.
During the first two trimesters a thyroidectomy performed after suitable prepar-
ation causes little risk to the fetus, but during the last trimester an operation
may precipitate labour and for this reason antithyroid drug treatment is often
preferred. Preoperative treatment must be suited to each patient's needs using
antithyroid drugs, iodides and propranolol to render the patient euthyroid.
Prolonged treatment with iodides (more than two weeks) must be avoided
because of the risk of goitre formation in the fetus. Instead, the beta-adrenergic
blocking drug propranolol may be used to control the peripheral manifestations
of the disease. Postoperatively it is advisable to put the patient on full doses
of thyroxine replacement if the TSH level rises, and to reassess the need for
continuing therapy after delivery (Tunbridge and Hall, 1975).
While the results of surgery for thyrotoxicosis in pregnancy are satisfactory
(Talbert et al, 1970; Emslander et al, 1974) many physicians prefer to manage
thyrotoxic patients with antithyroid drugs. Methods of employing these agents
in pregnancy remain controversial. Some recommend antithyroid drugs combined
with thyroxine replacement (Selenkow et al, 1973; Prout, 1975) while others
(Hamburger, 1972; Mestman et al, 1974; Tunbridge and Hall, 1975) advise the
use of antithyroid drugs alone. The divergence of these views stems largely
from inadequate information as to the extent to which thyroid hormones cross
the placenta from mother to fetus and vice versa. Results with both methods,
properly applied, appear to yield equally good results. No final conclusion was
reached in a recent debate on the merits or demerits of combined therapy for
thyrotoxicosis in pregnancy (Hamburger, 1972; Selenkow, 1972). Until recently,
our preference had been for the combined antithyroid-drug-thyroxine regime
which had been used to treat the majority of patients attending the joint ante-
natal endocrine clinic in the Royal Maternity Hospital, Belfast. The aim was to
use the smallest dose of an antithyroid drug to control symptoms after which
a supplemental dose of thyroxine (0.1 to 0.2 mg daily) was added to maintain
euthyroidism in the mother. Carbimazole has been the drug of choice, and is
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(5 mg six-hourly) or less once control has been achieved. Other suitable drugs
are propylthiouracil, PTU (100 mg eight-hourly for more severe cases and 50
mg six-hourly for milder ones) and methimazole (similar to carbimazole). More
recently, propylthiouracil has been shown not only to block glandular synthesis
of T4, but also to inhibit the conversion of thyroxine to triiodothyronine extra-
thyroidally (Abuid and Larsen, 1974). For this reason, PTU may possess a small
advantage over carbimazole which does not exert this extrathyroidal effect.
Propranolol may be given without risk in pregnancy until near term. Normally
it is used to control symptoms until the action of antithyroid drugs on hormone
synthesis takes effect. Propranolol has been suggested as an alternative to
antithyroid drugs (Langer et al, 1974) but its use cannot be recommended as
sole therapy in pregnancy, because it is impossible to predict those patients who
will respond from those who will not (Lowe et al, 1976). Furthermore, it has
been shown that infants of women who were receiving propranolol were more
depressed at birth than the babies of those who had received placebo tablets.
Propranolol has an extra-thyroidal action and increases the production of rT3
while lowering the level of triiodothyronine.
Antithyroid drugs cross the placental barrier and if given in excess, may
cause an abortion, or hypothyroidism and a goitre in the fetus. Accordingly,
they must be given with care, in the smallest dose necessary to control the
hyperthyroidism and combined with thyroxine (0.1 to 0.2 mg) to maintain the
maternal free thyroxine index at a normal level. Where it is possible to monitor
the response to treatment with sequential TSH estimations thyroxine replacement
can be omitted (Tunbridge and Hall, 1975). Any rise in serum TSH above normal
indicates over-treatment and the need to reduce the dose of antithyroid drug.
This is now the preferred method of treatment in the Royal Maternity Hospital.
Control of the hyperthyroidism should be assessed on clinical grounds and
by serial estimation of the FTI, serum T4 and T3 and TSH. If there is to be
any deviation from normal, the patient should be allowed to remain slightly
hyperthyroid. Once good control is achieved, the rose of the antithyroid drug
can usually be reduced with safety for the remainder of the pregnancy. In the
majority, if the mother has remained euthyroid or or slightly hyperthyroid, the
child will be normal at birth. Rarely, the infant may have exophthalmos, a
goitre and congenital thyrotoxicosis. This results from maternal thyroid stimul-
ating immunoglobulins reaching the fetal thyroid via the placenta. Babies born
to thyrotoxic mothers should be screened for hyperthyroidism. Mothers of those
at greatest risk have pretibial myxoedema and severe apthalmopathy. In mild
cases, the condition remits spontaneously after four to six weeks when maternal
immunoglobulins are eliminated from the baby's circulation. If symptoms and
signs are severe, carbimazole (2.5 mg eight-hourly) is given for a few weeks
combined with iodine (Lugol's solution one drop three times daily) or propranolol
(2.5 to 8 mg six-hourly) may be used as sole therapy (Pemberton et al, 1974).
Antithyroid drugs are excreted in milk, so that babies born to mothers who are
receiving them must not be breast fed.
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if proper care is taken. In this series of sixty-eight pregnancies treated medically,
four babies were lost (5.8 per cent) and there were four infants with goitre
and neonatal Graves' disease. In one, the goitre was said to be retrosternal.
No infant was hypothyroid. Of the babies that died, two were anencephalics and
one had multiple congenital defects. If these are eliminated the corrected total
fetal loss was 1.4 per cent. In Table III these results are compared with those
obtained by other authors.
TABLE III
Fetal loss in thyrotoxic patients treated in pregnancy
Method of treatment and number
of pregnancies
Antithyroid Fetal
Antithyroid drug and loss
Authors Surgery drug alone thyroxine (%)
supplement
Herbst and Selenkow 1965 0 0 32 9.4
Bokat 1968 0 41 0 4.7
Enslander et al 1974* 274 0 0 8.0
Mujtaba and Burrow 1975 0 68 0 15.0
Royal Maternity Hospital,
Belfast 1979 3 5 63 7.0
* Combined series from the literature.
In the remaining five patients, thyroidectomy was performed in three. Two
were untreated because they were seen late in pregnancy.On of these was the
first case of T3 thyrotoxicosis recognized in the Royal Maternity Hospital
(Martin et al, 1976).
HYPOTHYROIDISM
Is is rare for patients with significant hypothroidism to conceive (Echt and
Doss, 1963), and the incidence of spontaneous abortion and stillbirth is increased
(Man et al, 1951). Usually, patients become pregnant after they have been
treated for previously diagnosed hypothyroidism.
The clinical features of hypothyroidism are well known but minor degrees
may be overlooked because of the physical changes that accompany normal
pregnancy. Attention should be focussed on an excessive gain in weight, dry
skin, undue fatigue, cold intolerance, pallor not supported by anaemia and
delayed relaxation of the ankle jerk. The diagnosis is established by finding an
elevated TSH (10 ,U/ml or greater), a low T4, T3 and FTI. Treatment with
thyroxine (0.1 to 0.2 mg daily) must be sufficient to achieve euthyroidism which
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upper normal level and a T3 T4 and PBI in the normal pregnant range. If a
patient diagnosed previously becomes pregnant, replacement treatment is
continued and the dose adjusted to ensure adequate suppression of the TSH
level. Patients with partial degrees of thyroid insufficiency (subclinical hypo-
thyroidism) picked up by routine assay of TSH (Evered et al, 1973) should
receive adequate substitution therapy until the termination of pregnancy, after
which thyroid function may be reassessed.
Occasionally, patients with untreated hypothyroidism may conceive and carry
their pregnancy successfully to term (Hodges et al, 1952; Echt and Doss, 1963)
and their offspring have been reported to be normal. There were two patients
with hypothyroidism who gave birth to normal infants in this series (Kennedy
and Montgomery, 1978). Temporary amelioration of maternal hypothyroidism
as the consequence of fetal thyroid hormone production was observed in one
case. In contrast, a number of studies of human hypothyroidism have shown
an increased incidence of physical and mental abnormalities in the offspring,
in particular, permanent defects in the central nervous system (Man et al, 1958).
Man (1972) reported an increased incidence of low mental scores in infants
born to inadequately treated "hypothyroxinemic" mothers compared to euthyroid
controls. However, the diagnosis of "hypothyroxinaemia", based on a low BEI
and clinical features unsupported by other biochemical findings, appears to be
insufficient evidence upon which to judge the effect of maternal thyroid hypo-
function on the infant's mental development. The subject needs to be restudied
using direct hormone assays, in particular TSH, to enable maternal thyroid
function to be determined with confidence.
In this series, three of the hypothyroid mothers' babies died (4.6 per cent).
Two were premature and death was attributed to prematurity and respiratory
distress syndrome. Neither showed any thyroid pathology at postmortem. The
other was an intrauterine death at 39 weeks. The fetus had Fallot's tetralogy.
The mother had an abnormal GTT at 32 weeks and was classified as a potential
diabetic.
NON-TOXIC GOITRE
Enlargement of the thyroid is common in pregnancy (Crooks et al, 1964) but
its prevalence varies in different areas and on the clinical criteria adopted for
its diagnosis. It is much less in areas of high iodine intake (Crooks et al, 1967).
Simple goitres which enlarge in pregnancy probably never return to their non-
pregnant size.
The complications of haemorrhage into cysts, hypothyroidism and malignant
change should always be borne in mind. Haemorrhage may cause a sudden
increase in size of the gland, pain and dyspnoea. The blood-filled cyst may be
tender. A thyroid scintiscan is contraindicated in pregnancy but ultrasound is
safe and gives information about the nature of a suspicious nodule (Ramsay and
Meire, 1975). There is evidence that patients with a goitre in pregnancy may not
always be able to maintain euthyroidism, so it is important to assess thyroid
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mild. Thyroxine must be given if the TSH level rises and the FTI falls below
normal. Malignant disease must be considered if the voice is hoarse, if the gland
is painful or enlarges rapidly, or if examination shows it to be hard, fixed or
associated with enlarged lymph nodes.
The development of a single nodule in the thyroid during pregnancy requires
careful assessment. If the nodule is hard, painful or fixed or has enlarged rapidly
it should be removed without delay. If none of these features is present it
probably is safe to observe the patient or to prescribe suppressive therapy with
thyroxine. Further investigation of the lesion with appropriate radioiodine tests
can then be undertaken after delivery.
Nodular goitres usually enlarge during pregnancy. Provided normal thyroid
function is maintained and there are no obstructive features or other complicating
features, treatment of the goitre is unnecessary. Occasionally, patients with
congenital biosynthetic errors of thyroid hormone synthesis of mild degree,
become pregnant. All of these ultimately interfere with hormone production and
cause hypothyroidism and formation of a goitre. They can be effectively treated
in pregnancy with thyroxine.
In this series of 59 pregnancies in patients with non-toxic goitre, two babies
were lost, an incidence of 3.3 per cent.
CARCINOMA OF THE THYROID
The development of corcinoma of the thyroid during pregnancy is very rare.
The main difficulty is to recognize the early case which does not show charact-
cristic signs. The only safe course is to remain suspicious in every patient with
thyroid disease and to consider the possibility of malignancy in every goitre. A
nodule, which is apparently single and develops fairly quickly is the most likely
presentation and usually denotes a papillary growth. It must be differentiated
from a thyroid cyst with or without haemorrhage into it or an area of focal
thyroiditis. However, if suspicion of malignancy is high the neck must be
explored forthwith. Rapidly expanding tumours of the thyroid which are thought
to be carcinomatous must be removed promptly without regard to the pregnancy.
A previous history of carcinoma of the thyroid is not a contraindication to preg-
nancy, nor does the pregnancy adversely affect the prognosis of the cancer
(Rosvoll and Winship, 1965). This observation has been amply confirmed in
the present series. Most commonly the two conditions are seen together in
women who have previously been treated for papillary carcinoma of the
thyroid and who are on suppressive thyroxine treatment. They should be watched
for signs of recurrence and thyroxine suppression should be continued unaltered.
Ten of our patients previously treated for carcinoma (papillary 8, follicular l,
medullary 1) had 13 children without loss between them.
THYROIDITIS
Subacute thyroiditis and chronic lymphotcytic thyroiditis may rarely com-
plicate pregnancy. The former causes painful swelling of the gland which may
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course is subacute and the fever which is low or moderate, persists for several
weeks. Signs in the thyroid usually resolve in two to four months. Occasionally
the course is chronic and swelling of the thyroid persists much longer. Eventually,
resolution is complete and late sequelae have not been observed. Confirmation
of the diagnosis may be difficult because radioactive iodine uptake tests are
contraindicated. The ESR is always raised and low titres of thyroid antibodies
may be found. These combined with the clinical features and tender thyroid
are usually sufficient to suggest the correct diagnosis. Treatment with steroids
is highly effective but is usually contraindicated in the first trimester because
there may be increased risk of congenital abnormalities (Popert, 1962). Other
methods which are probably less effective, are antithyroid drugs (carbimazole
30mg daily for two to three weeks) or suppression with thyroxine. Occasionally,
a patient presents with a diffuse or hard enlargement of the thyroid and some-
times features of hypothyroidism. Estimation of the thyroid autoantibodies will
confirm the diagnosis of chronic lymphocytic thyroiditis (Hashimoto's thyroiditis).
Treatment with thyroxine,, whether thyroid function is depressed or not, is
necessary and the results are satisfactory. Thyroiditis (Table II) was observed
in eight pregnancies in this series. No adverse effect on fetal development was
seen.
FETAL RESULTS
Hyperthyroidism in pregnancy has been reported to be associated with a
slight increase in perinatal mortality and a significant increase in the frequency
of low birth weight babies (Niswander and Gordon, 1972). It is uncertain if
there is a real increase in the incidence of congenital abnormalities or if anti-
thyroid drugs could be a contributory factor.
TABLE IV
Thyroid disease in pregnancy. Fetal loss 1963-78.
Total
Neonatal fetal Perinatal
Disease Number Abortions Stillbirth death loss mortality
(%) (%)
Hyperthyroidism 73 1 4 0 5(6.8) 4(5.4)
Hypothyroidism 64 0 1 2 3(4.6) 3(4.6)
Non-toxic goitre 59 0 2 0 2(3.3) 2(3.3)
Miscellaneous
group 112 1 4 1 6(5.3) 5(4.4)
Total 308 2 11 3 16(5.1) 14(4.5)
311 fetuses - 3 sets of twins
78Table IV shows fetal loss for the whole series. The hyperthyroid group had
the highest total fetal loss and perinatal mortality, but allowing for the small
numbers involved there is really not much difference between the groups. During
the period under review the hospital perinatal mortality varied between 65.44
per 1,000 in 1963 and 20.46 per 1,000 in 1977 and the same steady downward
trend was observed in all the thyroid groups studied. Only the hyperthyroid and
miscellaneous groups come near the maximum hospital perinatal mortality rate.
Both these, however, and indeed the other groups were heavily weighed with
congenital abnormalities and complications unlikely to be connected with
thyroid disease (Table V).
TABLE V
Causes of fetal death in thyroid disease in pregnancy unlikely to be related to
thyroid disease
Group Cause of fetal death
Hyperthyroidism Anencephaly 2
Multiple congenital defects 1
Hypothyroidism Fallot's tetralogy with stillbirth 1
Non-toxic goitre Multiple congenital defects Trisomy D I
Miscellaneous group Anencephaly 1
Severe Rhesus isoimmunization 1
Total 7
In the hyperthyroid group there were two anencephalics and one infant with
multiple congenital defects, while in the miscellaneous group there was one
anencephalic and one case of severe Rhesus isoimmunization. If these are
eliminated the perinatal mortality for the hyperthyroid group becomes 1.3 per
cent and for the miscellaneous group 2.6 per cent, while for all groups it is
2.2 per cent. On balance, therefore, there is no evidence to suggest that thyroid
disease contributes adversely to the outcome of pregnancy. Furthermore, there
was no evidence to support the view that thyrotoxic mothers produce babies of
low birth weight. The mean birth weight of the last 14 babies born to treated
thyrotoxic mothers in this series was 3170 g.
None of the 311 infants was hypothyroid. Goitres were observed in four
babies born to mothers with treated hyperthyroidism and all had neonatal
Graves' disease. One mother, with severe Graves' disease and a very high titre of
thyroid stimulating immunoglobulins, gave birth to two affected babies in
successive pregnancies. Both infants responded well to treatment with prop-
ranolol.
The current view that antithyroid drug treatment has no ill effects on fetal
development has not gone unchallenged and some of the workers have expressed
concern about possible adverse effects of antithyroid drugs on the development
79of the central nervous system of the fetus. In Europe, for example, it is cust-
omary to give oral contraceptives to women receiving antithyroid medication for
hyperthyroidism. Recently, McCarroll et al (1976) investigated 25 children born
to women treated with carbimazole in the years 1960 to 1971 inclusive and
assessed their growth and psychological and intellectual development against
carefully matched controls born in the same week in hospital. It was apparent
that the use of carbimazole in pregnancy had no injuriouis effects on subsequent
growth and intellectual development of the children. Greenman et al (1962)
and Burrow et al (1968) came to similar conclusions after investigating the use
of propylthiouracil in pregnancy. These results, therefore, lend no support to the
view that antithyroid drug treatment in pregnancy is harmful for the mental
or physical development of the fetus.
SUMMARY
Changes in thyroid function in pregnancy and the nature of thyroid disease
seen in the Royal Maternity Hospital, Belfast, over a 16-year period, are reviewed.
All patients with a goitre or a previous history of thyroid disease need careful
assessment of thyroid function. If there is any departure from normal they
need appropriate treatment and careful follow-up for the remainder of the
pregnancy. Therapeutic measures available for the treatment of hyperthyroidism
are discussed. Antithyroid drugs may be given without risk to the developing
fetus.
Contrary to popular belief, hypothyroid patients can conceive and deliver
healthy infants without treatment. The phenomenon of amelioration of the
mother's hypothyroidism during pregnancy as the result of transplacental passage
of fetal thyroid hormone to the mother is noted. It is considered that thyroid
disease in pregnancy, provided that it is recognized and correctly treated, does
not adversely affect the outcome of the pregnancy.
ACKNOWLEDGMENTS
I wish to thank the obstetricians of the Royal Maternity Hospital for referring patients
to me and especially Professor J. M. G. Harley for his help in caring for these patients in
the joint Antenatal Metabolic/Endocrine Clinic. My thanks are also due to the nursing staff
(Sisters M. Murphy, R. E. Good and E. A. Archer) and metabolic registrars who havc
assisted me over the years; and to Miss May Weller for secretarial assistance.
REFERENCES
ABUID, J. and LARSEN, P. R. (1974). Triiodothyronine and thyroxine in hyperthyroidism;
comparison of the acute changes during therapy with antithyroid drugs. Journal of
Clinical Investigation, 54, 201.
BECKER, W. F. and SUDDUTH, P. G. (1959). Hyperthroidism and pregnancy. Annals of Surgery,
149, 867.
BELL, T. K., BOYLE, D. A., MONTGOMERY, D. A. D. and TODD, S. J. (1974). An evaluation of
absorbent granule kits for determining serum thyroxine concentration and free thyroxine
in the diagnosis of thyroid function. Journal of Clinical Pathology, 27, 372.
BOKAT, M. A. (1968). Treatment of hyperthroidism during pregnancy. In. Clinical Endoc-
rinology II (Ed. Astwood, E. B. and Cassidy, C. E.) pp.236-243. New York: Grune &
Stratton.
80BURROW, G. N., BARTSOCSAS, C., KLATSKIN, E. H. and GRUNT, J. A. (1968). Children exposed
in utero to propylthiouracil. Subsequent intellectual and physical development. American
Journal of Diseases of Children, 116, 161.
CHOPRA, I. J. and CRANDALL, B. F. (1975). Thyroid hormones and thyrotropin in amniotic
fluid. New England Journal of Medicine, 293 740.
CROOKS, J., ABOUL-KHAIR, S. A., TURNBULL, A. C. and HYITEN, F. (1964). The incidence of
goitre during pregnancy. Lancet, ii, 334.
CROOKS, J., TULLoc, M. I., TURNBULL, A. C., DAVIDSSON, D., SKULAsoN, T. and SNAEDAL, G.
(1967). Comparative incidence of goitre in pregnancy in Iceland and Scotland. Lancet ii,
625.
EcHT, C. R. and Doss, J. F. (1963).Myxedema in pregnancy. Obstetrics and Gynecology,
22, 615.
EMSLANDER, R. F., WEEKS, R. E. and MALKASIAN, G. D. (1974). Hyperthroidism in pregnancy.
Medical Clinics of North America, 58, 835.
EVERED, D. C., ORMSrON, B. J., SMITH, P. A., HALL, R. and BIRD, T. (1973). Grades of
hypothyroidism. British Medical Journal, i, 657.
FISHER, D. A., DUSSAULT, J. H., HOBEL, C. J. and LAM, R. (1973). Serum and thyroid gland
triiodothyronine in the human fetus. Journal of Clinical Endocrinology and Metabolism,
36, 397.
GOLUBOFF, L. G., SISSoN, J. C. and HAMBURGER, J. I. (1974). Hyperthyroidism associated with
pregnancy. Obstetrics and Gynecology, 4, 107.
GREENMAN, G. W., GABRIELSON, M. O., HOWARD-FLANDERS, J. and WESSEL, M. A. (1962).
Thyroid dysfunction in pregnancy. Fetal loss and follow-up evaluation of surviving
infants. New England Journal of Medicine, 267, 426.
HAMBURGER, J. I. (1972). Management of the pregnant hyperthyroid. Obstretrics and Gyne-
cology, 40, 114.
HAwE, P. and FRANcIs, H. M. (1962). Pregnancy and thyrotoxicosis. British Medical Journal,
ii, 817.
HERBSr, A. L. and SELENKow, H. A. (1965). Hyperthyroidism during pregnancy. New England
Journal of Medicine, 273, 627.
HoDGEs, R. E., HAMILTON, H. E. and KEETTEL, W. C. (1952). Pregnancy in myxedema.
Archives of Internal Medicine, 90, 863.
KENIMER, J. G., HERSHMAN, J. M. and HIGGINS, H. P. (1975). The thyrotopin in hyatidiform
moles in human chorionic gonadotrophin. Journal of Clinical Endocrinology and
Metabolism, 40, 482.
LANGER, A., HUNG, C. T., MCANULTY, J. A., HARRIGAN, J. T. and WASHING'TON, E. (1974).
Adrenergic blockade. A new approach to hyperthyroidism during pregnancy. Obstetrics
and Gynecology, 44, 181.
LOWE, D. C., HADDEN, D. R., MONTGOMERY, D. A. D. and WEAVER, J. A. (1976). Propranolol
as sole therapy for thyrotoxicosis; long-term follow-up. In Thyroid Research, Proceedings
of the Seventh International Thyroid Conference, Boston, 1975, pp. 429-433, Amsterdam;
Excerpta Medica.
MCCARROLL, A. M., HUTCHINSON, M., MCAULEY, R. and MONTGOMERY, D. A. D. (1976).
Long-term assessment of children exposed in utero to carbimazole. Archives of Disease
in Childhood, 51, 232.
MAN, E. B. (1972). Thyroid function in pregnancy and Infancy. Critical Reviews of Clinical
and Laboratory Science, 3, 203.
MAN, E. B., HEINEMAN, M., JOHNsoN, C. E., LEARY, D. C. and PETERS, J. P. (1951).
Precipitable iodine of serum in normal pregnancy and its relation to abortions. Journal
of Clinical Investigation, 30, 137.
81MAN, E. B., SHAVER, B. A. Jr. and CROOKE, R. E. (1958). Studies of children born to women
with thyroid disease. Anerican Journal of Obstetrics and Gynecology, 75, 728.
MARTIN, D. H., MONTGOMERY, D. A. D. and HARLEY, J. M. G. (1976). The occurrence of T3
thyrotoxicosis in pregnancy. Irish Journal of Medical Science, 145, 92.
MESrMAN, J. H., MANNING, P. R. and HODGMAN, J. (1974). Hyperthyroidism and pregnancy.
Archives of Internal Medicine, 134, 434.
MUJTABA, Q. and BURROW, G. N. (1975). Treatment of hyperthyroidism in pregnancy with
propylthiouracil and methimazole. Obstetrics and Gynecology, 46, 282.
NISWANDER, K. R. and GORDON, M. (1972). The Women and their Pregnancies. Philadelphia,
London, Toronto: W. B. Saunders, p.246.
PEMBERTON, P. J., MCCONNELL, B. and SHANKs, R. G. (1974). Neonatal thyrotoxicosis treated
with propranolol. Archives of Disease in Childhood, 49, 813.
PROPERT, A. J. (1962). Pregnancy and adrenocortical hormones. Some aspects of their inter-
action in rheumatic diseases. British Medical Journal, i, 967.
PRour, T. E. (1975). Thyroid disease in pregnancy. American Journal of Obstretrics and
Gynecology 122, 669.
RAMSAY, I. D. and MEIRE, H. (1975). Ultrasonics in the diagnosis of thyroid disease.
Clinical Radiology, 26, 191.
ROSVOLL, R. V. and WJNSHIP, T. (1965). Thyroid carcinoma and pregnancy. Surgery,
Gynecology and Obstetrics, 121, 1039.
SELENKow, H. A. (1972). Antithyroid-thyroid therapy of thyrotoxicosis in pregnancy.
Obstetrics and Gynecology, 40, 117.
SEurKow, H. A., BIRNBAUM, M. D. and HoLLANDER, C. S. (1973). Thyroid function and
dysfunction during pregnancy. In Clinical Obstetrics and Gynecology (Ed. Ryan, K. J.),
pp.66.408. Hagerstown, Maryland: Harper and Rowe.
TALBERT, L. M., T1HOMAS, C. G. Jr., HOLT, W. A. and RANKIN, P. (1970). Hyperthyroidism
during pregnancy. Obstetrics and Gynecology, 36, 779.
TUNBRIDGE, W. M. G. and HALL, R. (1975). Thyroid function in pregnancy. Clinics in
Obstetrics and Gynecology, 2 381.
WERNR, S. C. (1967). Two panel discussions on hyperthyroidism. I. Hyperthyroidism in
the pregnant woman and the neonate. Journal of Clinical Endocrinology and Metabolism,
27, 1637.
82